Device Trial Radar · NCT04087811
Postmarket Registry for Evaluation of the Superion® Spacer
Last checked: Nov 20, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,674
Actual
Start
Nov 28, 2016
Primary completion
Mar 1, 2021
Study completion Mar 1, 2021
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Sep 12, 2019
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To gather evidence documenting the performance and clinical outcomes associated with treatment of moderate degenerative lumbar spinal stenosis using the Superion® Indirect Decompression System (IDS).
Conditions
- Lumbar Spinal Stenosis
Interventions
Superion® Indirect Decompression System (IDS)Device
Superion® Indirect Decompression System (IDS) (Superion® implant)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Vertiflex® Patient Satisfaction SurveyTime frame: 3 Week Follow-Up Visit
- Vertiflex® Patient Satisfaction SurveyTime frame: 6 Month Follow-Up Visit
- Vertiflex® Patient Satisfaction SurveyTime frame: 12 Month Follow-Up Visit
Locations
66 sites in 1 country. Site status is shown where the registry gives one.
(ACT) Alabama Clinical Therapeutics, LLC
Birmingham, Alabama
HOPE Research Institute
Phoenix, Arizona
HOPE Research Institute
Scottsdale, Arizona
63 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.